is the most common central nervous system neoplasm in children and only rarely presents in the adult population. Recent molecular biology findings have characterized MB as a heterogeneous neoplasm distinguished by well-defined tumour subsets each with specific histologic and molecular features. Available immunohistochemical stains can now be used to differentiate the distinct molecular types of MB. This report analyzed the histopathologic and neuroradiologic features of two new cases of adult MB. Imaging studies in these patients revealed the morphological appearance of high-grade, well-circumscribed heterogeneous tumours with necrosis, located laterally within the posterior cranial fossa. Histopathology of resected samples demonstrated high-grade tumours (WHO grade IV) containing sheets of undifferentiated neural cells with high mitotic activity and evidence of necrosis. The histopathologic and molecular characteristics of these cases of MB are reviewed for potential applications in new molecular methods of imaging.
Introduction
Medulloblastoma (MB) is the most common central nervous system (CNS) neoplasm in children, representing 20% of supratentorial CNS tumours in this age group 1 , but constituting only 1.9% of all CNS tumours in adult populations.
Recently, the World Health Organization (WHO) defined MB as a grade IV neoplasm with variable biologic behaviour and a wide histopathologic spectrum 2 . Over the last two decades, advances in MB tumour biology have revealed that MB is a heterogeneous neoplasm characterized by well-defined tumour subsets with specific histopathologic and molecular features 2, 3 . A combination of clinical, neuroradiologic, pathologic, and molecular data can be used to stratify patients into risk groups and may lead to new risk-adaptive approaches for therapy 3, 4 . For this reason, the new classification of MB based on prognostic and treatment markers is highly promising. MB formation and growth have been associated with multiple molecular dysfunctions [2] [3] [4] . Some molecular and cytogenetic alterations include TP53 mutation and cyclin-D1 up-regulation 5, 6 . Activation of the Wnt pathway has also been observed in 10-15% of MBs and has recently been described as a marker of favourable patient outcome 3, 7 . Wnt proteins are a secreted cysteine-rich glycoprotein group, which includes at least 19 identified members. Wnt signalling pathways are categorized as "canonical" (β-catenin-dependent) and "non-canonical" (planar cell polarity or Wnt/Ca2+ or protein kinase A). Activation of the Wnt pathway inhibits glycogen synthase kinase-3b-dependent phosphorylation of β-catenin. Stabilized, hypophosphorylated β-catenin translocates into the nucleus and interacts with transcription factors in the T-cell factor/lymphoid enhancer factor-1 (TCF/LEF-1) family. This interaction then results in increased expression of genes such as c-MYC, which ultimately establishes the oncogenic phenotype 7,8 .
The molecular advances described above have been documented mainly in paediatric MBs. The lower incidence of adult MB, com-bined with a less well-defined treatment strategy and more frequent late relapses, has hindered similar progress in this age group. As a result, identification of molecular risk factors specific to adult MB is restricted by small sample size and remains inconclusive. Attempts have been made to apply paediatric MB data to adult forms of the disease. However, studies have documented differences in localization, cell of origin, histopathologic features, tumour cell differentiation, and treatment outcome between childhood and adult MBs.
In summary, current prognostic immunohistochemical markers include: p53, the product of a well-known tumour suppressor gene crucial in tumour progression 5, 6 , cyclins, expressed in the developing embryonic CNS and which may reflect differences in the malignant potentials of MBs 6,10 , and nuclear β-catenin, the ultimate effector factor in the canonical Wnt signalling cascade 8, 11 .
Here, we describe two cases of adult medulloblastoma. We characterize the clinical manifestations and correlate neuroradiologic and histopathologic characteristics. Finally, we review new advances in the molecular biology of medulloblastoma to study its applicability to future molecular imaging.
Clinical Case 1
A 47-year-old woman presented with a fourmonth history of constant headache and left hemiparesis. She was admitted conscious, oriented, and without strength alterations or meningeal signs. Cranial computed tomography (CT) and magnetic resonance imaging (MRI) scans demonstrated a 2.3 cm left cerebellar mass ( Figure 1 ). Functional MRI was not available. The tumour was surgically resected, and subsequent histopathologic examination identified a primitive neoplasm containing solid sheets of large pleomorphic cells with minimal cytoplasm and anaplastic nuclei separated by collagenous areas (Figure 1 ). The neoplastic cells were positive for FLl-1, synaptophysin, cyclin-D1, p53, CD56, neuronal specific enolase (NSE) and CD99 with a proliferation index Ki67 of 80% ( Figure 1 ).
The patient was diagnosed with adult desmoplastic MB. She was then treated with multiple radiotherapy sessions of 2 Gy/day totalling 54 Gy over the treatment period, and eight cycles of chemotherapy with vincristine, cisplatin and. After an initial period of remis-sion, the patient's tumour recurred, and she died three months later with vertebral bone metastasis.
Clinical Case 2
A 52-year-old woman presented with headaches and vertigo with mild nystagmus triggered by rapid movements to the right. She was non-oriented to time, space, or location. The cranial CT scan revealed a cerebellar mass associated with obstructive hydrocephalus. The MRI showed a 2.4 cm round heterogeneous lesion in the left cerebellar hemisphere, hypointense on T1, and isointense on T2 and fluid attenuated inversion recovery (FLAIR) ( Figure 2 ). A ventricular drain was placed, and the mass was surgically resected. Histopathologic examination demonstrated a primitive malignant neoplasm composed of pleomorphic cells with atypical mitoses ( Figure 2D ). Immunohistochemical analysis reported that tumour cells were positive for FLI1, synaptophysin, cyclin-D1, p53, NSE and CD56. The proliferation index (Ki-67) was 90%. A diagnosis of classic adult MB was made ( Figure 2 ). Afterwards, the patient received chemotherapy with vincristine 2 mg/week for six weeks and radiotherapy up to a total dose of 36 Gy. Extension studies with MRI and osseous gammagraphy showed multiple metastases in vertebral bones and cranium. She died within one year of follow-up.
Discussion
Bailey and Cushing coined the term 'medulloblastoma' to describe a confined tumour with primitive neuroglial characteristics whose cells can adopt neuronal, glial, or muscular characteristics and appearing at the cerebral vermis or around the fourth ventricle 1,2 . The annual incidence of MB in adults is approximately 0.24 per 100,000 persons, with the highest incidence in the 20-34 year age group 7 . Gender distribution depends on the observed series, but usually the disease is more frequent among males than females with a 2:1 ratio in adult patients 1 . Survival rates of patients with MB have significantly improved over the years due to developments in diagnostic techniques, neurosurgery, chemotherapy, radiotherapy, and supportive care 1, 4 . However, MBs remain both an important cause of cancer-related deaths in children and a rare but catastrophic disease in adults.
For many years, clinical cancer staging systems have been considered the most useful method for stratifying MB patients into prognostic risk groups. However, in recent decades, multiple immunohistochemical markers have been developed to generate better prognostic profiles and more individualized therapy for these patients 2,3 . Gene-expression profiling studies have revealed four molecular subtypes of MB, each characterized by a distinct genetic profile, oncogenic pathway, and clinical outcome. Subgroup A is defined by Wnt signalling, subgroup B by Hh signalling, and subgroups C and D by expression of neuronal differentiation and photoreceptor genes 7, 8 . The data further indicate that although most Wnt tumours are classic MB and most Hh tumours are desmoplastic MB, these subgroups always cluster together, suggesting biological similarity 3, 8 .
The most common clinical manifestations of medulloblastomas in adult patients are headaches (93% of cases) 2,3 . Other symptoms include nausea, vomiting, and ataxia, resulting from high intracranial pressure and cortical dysfunction 3, 4 . Cranial CT scan and MRI are initial diagnostic tools and can demonstrate typical characteristics of high grade tumours including mass effect, hydrocephalus, tumour calcifications, cystic regions, and areas of necrosis 4 . On radiologic studies, the macroscopic features The differential diagnosis for these neoplasms includes neuroma, meningioma, ependymal cysts, cholesteatoma, ependymoma, glomus jugular tumours, and metastases. The wide differential makes histopathological analysis fundamental for a correct diagnosis; however, due to the tumour's location, it is often difficult to perform biopsy. In this scenario, it is critical to have accurate molecular imaging strategies for diagnosis of MB. Molecular imaging studies can further benefit pre-operative evaluation of disease extension and also decrease collateral surgical damage 12 .
The histopathologic characteristics of MB are similar in adults and children, but the desmoplastic subtype is more frequently seen in adults 11 . This tumour is composed of small, rounded, hyperchromatic cells with minimal cytoplasm and anaplastic nuclei with frequent atypical mitoses. The hypercellularity of this neoplasm is responsible for increased capture of contrast agent. In some cases, neuroblastic differentiation can be seen with Homer- Figure 2 A radiologic and histopathologic overview of case 2 is presented. In this case the MRI contrasted with gadolinium shows in axial (A), sagittal (B) and coronal cuts (C), an intra-axial lesion with a mild shift on the left cerebellar hemisphere and involvement of the paravermian right soft tissue with minimum shift. This lesion corresponds to a high grade primitive tumour composed of large cells (D, HE 400×), positive for synaptophysin (E, 400×), cyclin-D1 (F, 400×) and p53 (G, 400×), and negative for β-catenin (H, 400×).
A B C D E F G H
Wright rosette formation. These cells typically are positive for NSE and synaptophysin, and also have focal immunoreactivity to GFAP. In cytogenetic studies, isochromosome 17q or 17p can be found (TP53 location). In addition, molecular overexpression of c-MYC or n-MYC by 5-30% is associated with a worse prognosis 13, 14 . The desmoplastic variant is associated with nevoid basocellular carcinoma and has increased fibrous reaction due to leptomeningeal cell proliferation. These patients have a better prognosis than those with classic variants of the neoplasm. Comprehensive immunohistochemical panels based on the identification of β-catenin nuclear expression have been used in paediatric and adult MB 7, 11 . Cyclins or cyclin-dependent kinases (CDKs), and CDK-inhibitors regulate the phosphorylation activity of the retinoblastoma protein (pRb), which offers control in the G1-S transition of the cell cycle. One such cyclin involved in the G1 phase is cyclin-D1, which appears to be the most strongly implicated in human carcinogenesis 6, 10 . On the other hand, use of p53 protein expression unequivocally predicts poor outcome in many human neoplasms, including standard-risk MB patients 5, 9 . Furthermore, the MB subgroup characterized by activation and mutation of the canonical Wnt pathway 3,7,8 is distinguished by nuclear β-catenin immunostaining, CTNNB1 mutations, and chromosome 6 loss, along with a favourable prognosis and good response to standard therapies.
We use three markers, cyclin D1, p53 and βcatenin, to define different groups of adult MB, a neoplasm with difficult prognostic and thera-peutic stratification 13, 15, 16 . β-catenin expression can be used as a therapeutic marker, with the advent of Wnt inhibitors. The translation of this tissue-based molecular classification to molecular imaging strategies or techniques can bring therapeutic and prognostic knowledge prior to surgery, which can produce better treatment outcomes. The development of specific diffusible probes (antibodies or peptides), ligated to contrast agents, is under investigation 17, 18 .
Extension studies must be performed in the management of this high-grade CNS tumour due to its tendency to disseminate to cerebrospinal fluid (CSF) and different meningeal locations. After surgical resection, radiotherapy should also be used to diminish the probability of dissemination 14, 15 . Extracranial metastases to bones, lymph nodes, lungs, and liver can be observed in up to 5% of cases of MB, more than any other CNS tumour 2, 15 . Some authors recommend locoregional radiotherapy at doses of 54 Gy or higher on the posterior fossa to achieve better local control and an extra 35Gy dose to eliminate malignant cells in the CSF 16 . Paediatric studies have proven that the addition of chemotherapy (vincristine, CCNU, cisplatin and intrathecal methotrexate) may also improve outcome, resulting in increased usage in adult cases of MB 2,15 .
In conclusion, medulloblastomas are the most commonly observed primitive tumours of the CNS and are almost always found in children. However, in the rare event that these tumours present in adults, physician recognition of distinct neuroradiologic and histologic features is needed for optimal diagnosis and treatment.
